Amicus Therapeutics, Inc.
FOLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $2 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 9.3% | 23.5% | -16.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.4% | 90.2% | 90.7% | 90.1% |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 28.3% | -3.7% | -3.8% | 14.7% |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 10.2% | -15.8% | -17.3% | 9.8% |
| EPS Diluted | 0.056 | -0.08 | -0.07 | 0.049 |
| % Growth | 169.8% | -14.3% | -242% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |